TABLE 2.
Summary of total stilbenoid and control compound bioactivities in infectious SARS-CoV-2 assays
| Compound | EC50 for CPE scoring-based assay for: |
CC50 cell viability (μM) | EC50: viability restoration in infected cells for: |
EC50: yield reduction assay for: |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| WA1/2020 | B.1.1.7 | B.1.351 | WA1/2020 | B.1.1.7 | B.1.351 | WA1/2020 | B.1.1.7 | B.1.351 | ||
| Hopeaphenol | 10.2 μM | 14.8 μM | 2.3 μM | >100 | 23.4 μM | 7.8 μM | 7.5 μM | 13.5 μM | 11.4 μM | 8.8 μM |
| Vatalbinoside A | 13.8 μM | 4.0 μM | 3.6 μM | >100 | 18.8 μM | >50 μM | 11.3 μM | 19.1 μM | ||
| Vaticanol B | 37.0 μM | 32.4 μM | 25.3 μM | >100 | >50 μM | >50 μM | >50 μM | >50 μM | ||
| Resveratrol | >100 μM | ∼100 | >50 μM | |||||||
| REGN10933 | 0.16 nM | 0.013 nM | 9.2 nM | 0.25 nM | 0.10 nM | 0.97 nM | 0.17 nM | 0.011 nM | 2.2 nM | |
| Remdesivir | 2.5 μM | 1.5 μM | 1.4 μM | >10 | 7.3 μM | >10 μM | >10 μM | 1.0 μM | ||
| GC-376 | 3.9 μM | >10 | ||||||||